GAP214 

GAP214 is a monosaccharide lipid A analogue and TLR4/MD-2 complex modulator.GAP214 binds to the TLR4/MD-2 complex via hydrophobic interactions, salt bridges, and hydrogen bonds, induces dimerization of the complex to initiate intracellular signaling cascades.GAP214 functions as an immunostimulant and vaccine adjuvant, enhances antigen-specific IgG antibody production in a mouse model^[1].

GAP214 potently activates murine DC2.4 dendritic cells via the TLR4 pathway, inducing 3.5-fold higher IL-6 and 4.7-fold higher IL-12p70 secretion than PHAD, and increasing CD80⁺CD86⁺ double-positive cells to 17.98%^[1].
GAP214 potently activates murine RAW264.7 macrophages via the TLR4 pathway, inducing higher IL-6 and TNF-α secretion than PHAD, and increasing CD80⁺CD86⁺ double-positive cells to 14.47%^[1].
GAP214 potently activates human THP-1 monocytic cells, inducing higher IL-6 and TNF-α secretion than PHAD^[1].
GAP214 (10-100 μg/mL; 24 h) exhibits no significant cytotoxicity against HEK293 or B16F10 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GAP214 (17 μg per mouse per immunization; intraperitoneal injection; 3 doses at 2-week intervals) functions as a potent TLR4 agonist vaccine adjuvant in BALB/c mice, inducing IgG antibody titers 2.5-fold higher than the PHAD control after three immunizations, alongside robust DC activation, antigen-specific T cell responses, and memory T cell formation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1701.44

C₉₅H₁₈₂N₃O₁₉P

OC[C@@H]1[C@@H](OP(O)(O)=O)C(OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H](NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@H](OCC(CNC(C[C@H](O)CCCCCCCCCCC)=O)(CNC(C[C@H](O)CCCCCCCCCCC)=O)CO)O1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang ZM, et al. Design, synthesis and immunological evaluation of novel monosaccharide TLR4 agonists. Bioorg Chem. Published online March 3, 2026.  [Content Brief]